ストックスクリーナーアプリを入手
4.24
1.19%
0.05
前日終値:
$4.19
開ける：
$4.35
24時間の取引高:
343.28K
Relative Volume:
2.22
時価総額：
$343.15M
収益：
-
当期純損益:
$-31.64M
株価収益率:
-10.03
EPS:
-0.4226
ネットキャッシュフロー:
$-13.98M
1週間 パフォーマンス:
+1.44%
1か月 パフォーマンス:
+17.78%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$4.16
$4.35
1週間の範囲:
$4.04
$4.35
52週間の値動き範囲:
$3.51
$5.9299
Nervgen Pharma Corp Stock (NGEN) Company Profile
Compare NGEN vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NGEN
Nervgen Pharma Corp
|
4.24 | 339.10M | 0 | -31.64M | -13.98M | -0.4226 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nervgen Pharma Corp (NGEN) 最新ニュース
NervGen Pharma initiated with a Buy at Lucid Capital - TipRanks
NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference - Bitget
NGEN Options Volatility — NASDAQ:NGEN - TradingView — Track All Markets
NGEN Options Chain — NASDAQ:NGEN - TradingView — Track All Markets
Is NervGen Pharma still undervalued? - Cantech Letter
Lobbying Update: $50,000 of NERVGEN PHARMA CORP. lobbying was just disclosed - Quiver Quantitative
NGEN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia - Sahm
NervGen receives FDA alignment on Phase 3 trial for tetraplegia By Investing.com - Investing.com South Africa
NervGen Pharma Says Phase 3 Chronic Tetraplegia Study Design Aligns With US FDA - marketscreener.com
NervGen Wins FDA Alignment for Phase 3 RESTORE Trial in Chronic Tetraplegia - TipRanks
NervGen receives FDA alignment on Phase 3 trial for tetraplegia - Investing.com
NervGen Pharma aligns with FDA on RESTORE study following End-of-Phase 2 meeting - TipRanks
NervGen Pharma Corp. announces that patient enrollment for its Phase 1B/2a CONNECT-SCI clinical trial targeting individuals with quadriplegia due to subacute spinal cord injury is nearing completion. - Bitget
Nervgen Pharma announces successful end-of-phase 2 meeting and FDA alignment on Restore, a phase 3 registrational study of NVG-291 for chronic tetraplegia - marketscreener.com
Nervgen Pharma Announces Successful End-Of-Phase 2 Meeting And FDA Alignment On Restore, A Phase 3 Registrational Study Of Nvg-291 For Chronic Tetraplegia - TradingView — Track All Markets
Analysts Offer Insights on Healthcare Companies: Milestone Scientific (MLSS) and NervGen Pharma (NGEN) - The Globe and Mail
The Rise of 6 Emerging Therapies in a Critical Spinal Cord Injury Market Void | DelveInsight - The Manila Times
NervGen Pharma Corp. Stock Chart | NASDAQ: NGEN Stock Price - Bitget
This analyst loves NervGen Pharma - Cantech Letter
NervGen appoints regulatory and patient advocacy executives - Investing.com
NervGen Maps Path to Phase 3 as NVG-291 Data Strengthen Neuroreparative Ambitions - TipRanks
NervGen Pharma reports full year 2025 financial results and provides business updates - MarketScreener
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates - Bitget
NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Spinal Cord Injury Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment By DelveInsight | StemCyte, NervGen Pharma, VA Office of Research and Development, Kessler - Barchart
NervGen Pharma Corp.(TSXV: NGEN) dropped from S&P/TSX Venture Composite Index - marketscreener.com
NervGen Pharma (NGEN.US) Income Statements, Balance Sheet & Cashflow - Longbridge
NervGen Pharma Stock Quote, Share Price, News and Analysis - Longbridge
NervGen Pharma: I See Promise, But The Clock Is Ticking (Rating Downgrade) (NASDAQ:NGEN) - Seeking Alpha
NGEN.CA Stock Price, Quote & Chart | NERVGEN PHARMA CORP (TSX-V:NGEN) - ChartMill
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange - Sahm
NervGen Pharma to delist shares from TSX - TipRanks
NervGen Pharma (NGEN) to Voluntarily Delist from TSX Venture Exc - GuruFocus
NervGen Pharma to Delist from TSX Venture Exchange, Keep Nasdaq Listing as NVG-291 Advances - TipRanks
NervGen appoints regulatory and patient advocacy executives By Investing.com - Investing.com Nigeria
NervGen Pharma proposes amendment to warrant terms - MSN
NervGen Pharma price target raised to C$6.75 from C$5 at Stifel - TipRanks
Nanogen appoints Ruff as Chief Regulatory Affairs Officer, McSherry as SVP - TipRanks
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP of Patient Advocacy - geneonline.com
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs - The Manila Times
NervGen Pharma CFO to Retire as Company Advances Late-Stage SCI Program - TipRanks
Spinal Cord Injury Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals By DelveInsight | StemCyte, NervGen Pharma, VA Office of Research and Development - StreetInsider
NervGen Pharma (NGEN) Stock Analysis Report | Financials & Insights - Benzinga Japan
NGENFNervgen Pharma Corp Latest Stock News & Market Updates - Stock Titan
NervGen Pharma to Participate at Upcoming Investor Conferences - The Manila Times
Nervgen Pharma Corp (NGEN) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):